Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

275.12 -1.32 (-0.48%)
Streaming Delayed Price Updated: 10:57 AM EDT, May 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutic

< Previous 1 2 3 4 5 Next >
Expert Ratings For United Therapeutics
Via Benzinga
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier. 
Via Investor's Business Daily
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR), an undervalued stock with good fundamentals. 
Via Chartmill
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79. 
Via Investor's Business Daily
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
The Latest Analyst Ratings For United Therapeutics
Via Benzinga
Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock
Via Benzinga
Lung Disease-Focused United Therapeutics Says It Is A Compelling Investment Opportunity
United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge. 
Via Benzinga
UTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024
UTHR stock results show that United Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
NASDAQ:UTHR stands out as a stock that provides good value for the fundamentals it showcases.
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
Earnings Scheduled For February 21, 2024
Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
Via Benzinga
Earnings Outlook For United Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Bargain Hunter’s Portfolio: 7 Smart Stock Buys for the Shrewd Investor
Although several companies have seen their valuations blossom, you can still find bargain stocks if you know where to look. 
Via InvestorPlace
The 3 Most Undervalued Nasdaq Stocks to Buy in March 2024
Learn about these undervalued NASDAQ stocks teeming with the potential to bounce back and show great returns for investors this year. 
Via InvestorPlace
Game Changers: 3 Biotech Stocks That Could Be Multibaggers in the Making
These three companies represent the world of biotech stocks and offer a unique blend of high risk and potentially high reward. 
Via InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings
Legal battle unfolds as United Therapeutics challenges FDA's handling of Liquidia's drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial... 
Via Benzinga
Exposures Product Safety
This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate
United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Biotech Stocks Are on Fire: Here Are the Top 3 Picks for January
These biotech stocks offer exciting and disruptive solutions with the potential to expand to market caps worth trillions. 
Via InvestorPlace
Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
In the volatile world of biotech stocks, keeping an eye on the news is critical. Here are three companies to look out for. 
Via InvestorPlace
Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?
Liquidia Corp (NASDAQ: LQDA) stock jumped after a win in a pat 
Via Benzinga
7 Healthcare Stocks That Are Poised to Become the Next Unicorns
Discover healthcare stocks with remarkable potential for growth and "unicorn" status in the ever-evolving world of healthcare investments. 
Via InvestorPlace
Flying Car Stocks: What a Devastating Short Report Means for EHang
Hindenburg raised red flags for flying car stocks after releasing a short report on EH stock. Here's what investors should watch. 
Via InvestorPlace
EH Stock Alert: Hindenburg Slams EHang in New Short Report
EH stock is falling back to earth after Hindenburg Research issued a short report on the electric vertical take-off and landing (eVTOL) firm. 
Via InvestorPlace
Earnings Scheduled For November 1, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
Health Care Company United Therapeutics Announces Acquisition of Miromatrix Medical
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.